Related Experiment Video
Updated: Aug 14, 2026

Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis
Published on: January 31, 2025
Sulindac sulfone is most effective in modulating beta-catenin-mediated transcription in cells with mutant APC
Wen-Chi L Chang1, Lynette C Everley, Gordon R Pfeiffer
1Division of Population Science, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. wen-chi.chang@fccc.edu
Abstract:
Sulindac sulfone (FGN-1, Aptosyn), a metabolite of the nonsteroidal anti-inflammatory drug sulindac, lacks cyclooxygenase inhibitory activity. Although its ability to inhibit tumorigenesis in both carcinogen-treated animals and patients with familial adenomatous polyposis has been attributed to the induction of apoptosis, its complete mechanism of action remains unclear. The purpose of the present study was to determine the ability of sulindac metabolites to regulate cellular levels of beta-catenin and downstream targets of the adenomatous polyposis coli (APC)/beta-catenin pathway in vitro. Sulindac sulfone was consistently more potent than the sulfide metabolite in all analyses, significantly decreasing the expression of total cellular beta-catenin (50% of control), pro-caspase 3 (49%), cyclin D1 (51%), and PPARdelta (65%) in SW480 cells. No significant alteration in pro-caspase 3 or beta-catenin expression was found in HCA7, LS174, or Caco-2 cells treated with sulindac sulfone. A dose-dependent reduction in TCF-mediated transcriptional activity was also observed in SW480 cells. These data demonstrate that sulindac sulfone can modulate the APC/beta-catenin pathway in vitro and that its efficacy is dependent upon the mutational status of APC and beta-catenin.
Insights
Sulindac sulfone, a nonsteroidal anti-inflammatory drug metabolite, effectively reduces beta-catenin and related proteins in specific cancer cells. Its mechanism involves modulating the APC/beta-catenin pathway, depending on cellular mutations.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Sulindac sulfone, a metabolite of sulindac, lacks cyclooxygenase activity but is known to inhibit tumorigenesis.
- Its anti-cancer mechanism, often attributed to apoptosis induction, is not fully understood.
- The adenomatous polyposis coli (APC)/beta-catenin pathway is crucial in colorectal cancer development.
Purpose of the Study:
- To investigate the effect of sulindac metabolites on beta-catenin levels and the APC/beta-catenin pathway in vitro.
- To compare the potency of sulindac sulfone and its sulfide metabolite in regulating this pathway.
- To determine if sulindac sulfone's efficacy is dependent on the mutational status of APC and beta-catenin.
Main Methods:
- Treatment of various colon cancer cell lines (SW480, HCA7, LS174, Caco-2) with sulindac metabolites.
- Quantification of cellular levels of beta-catenin, pro-caspase 3, cyclin D1, and PPARdelta.
- Assessment of TCF-mediated transcriptional activity.
Main Results:
- Sulindac sulfone significantly decreased total cellular beta-catenin, pro-caspase 3, cyclin D1, and PPARdelta in SW480 cells.
- These effects were more potent than those observed with the sulindac sulfide metabolite.
- No significant changes in pro-caspase 3 or beta-catenin were observed in HCA7, LS174, or Caco-2 cells.
- A dose-dependent reduction in TCF-mediated transcriptional activity was noted in SW480 cells.
Conclusions:
- Sulindac sulfone can modulate the APC/beta-catenin pathway in vitro.
- The compound's efficacy is contingent upon the specific mutational status of APC and beta-catenin within the cells.
- These findings provide insights into the molecular mechanisms underlying sulindac sulfone's anti-cancer properties.
Related Concept Videos
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the adherens...
Abnormal Proliferation
Anaphase Promoting Complex
Inhibition of Cdk Activity
Positive Regulator Molecules
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...